Robert Frost. › pdf › News_Letter_2018.pdf · Best wishes to all of you. Dr. K. Sarat Chandra...

1CSI Newsletter Volume I : No. 1 | March 2018

Dear Colleagues,

Cardiological Society of India is just a year away from becoming a seventy year old body with a history that can make all of us proud by way of its academic tradition and practices and a heritage of bonhomie and brotherhood amongst cardiologist-fraternity in India. It has attained a stature by dint of which it is well-respected by other premier cardiac societies in the world like American College of Cardiology (ACC), European Society of Cardiology, World Heart Federation (WHF). The recently published “CSI Textbook of Cardiology: The Indian Perspective” is a piece of work that will unfold the “Indian data, ideas and ethos” to the rest of the world. Having walked miles to reach this juncture, CSI cannot yet afford to rest on its laurels as there are miles ahead to be traversed.

“But I have promises to keep, and miles to go before I sleep and miles to go before I sleep” – Robert Frost.

While over the seventy-two years since independence, India has earned the dubious distinction of becoming World Capital of diabetes, hypertension and coronary artery disease, CSI has done very little to generate public awareness to prevent the onslaught of these diseases and risk factors. We, Indians, as an “ethnic” entity have relied mostly on “Western Guidelines” because over the years we have not collated any data from our population to propel our own guidelines. Partly in view of the aforementioned deficiencies in our functioning, the policy-making bodies in the Government Sector of the country have often not acknowledged the credentials of CSI as a body.

It is high-time now esteemed members, that we shake-off our inertia and take a plunge to wipe-out these deficiencies. To kickstart the endeavour, we are immediately initiating the following moves.

i) Launch a “public awareness drive through electronic media at two extreme strata a) Primordial prevention – the “TEN COMMANDMENTS” to create a

heart healthy family and environment.”b) To propagate the profound necessity of “Early presentation” after onset of

chest pain in ACS.ii) To initiate “Registries” on Acute Decompensated Heart Failure (ADHF) and

Acute Coronary Syndrome (ACS). Eastern Zone has been chosen as a “pilot” zone to initiate the project in view of its relatively greater paucity of data.

The aforementioned endeavours are intended to portray CSI in the eyes of public and the Government as a body which is committed to the cause of reducing the burden of cardiovascular disease in the country and indigenizing cardiovascular medicine to the prevalent needs and socio-economic environment. In today’s scenario when community of physicians as a whole and cardiologists in

Message from Hony. General Secretary

2 CSI NewsletterVolume I : No. 1 | March 2018

particular are being subjected to various indignations, such endeavours are expected to buttress the image of our community to a significant extent. A “Public Education Hall” is also being envisioned in the “Indian Heart House” when the plan to expand the existing building takes shape. Thus, the current executives of the Society are bent on nurturing a dream to make CSI academically strong, organizationally productive, societally benevolent, nationally and internationally pre-eminent.

“Dreams, indeed, are ambition; for the very substance of the ambitions is merely the shadow of a dream” – William Shakespeare.

Long live CSI

Prof. Soumitra KumarHony. General Secretary Cardiological Society of India (CSI)


Dear Members,

Greetings to all of you!

We intend to do many new things in this year in the direction of research and increasing the visibility of CSI in the society. We want to take up research in cardiology in a big way and Dr. P.P. Mohanan, Sr. Vice President has been entrusted with the task of leading the research. It goes without saying that all the scientific papers produced from this research will be published in Indian Heart Journal only.

Consequent to Dr. Sandeep Mishra’s resignation, Dr. Manish Bansal, Consultant Cardiologist, Medanta Hospital, New Delhi is appointed as interim Editor for the year 2018. Dr. Manish Bansal has an excellent academic career and has a number of publications in his kitty. I am sure he will do an excellent job.

Dr. S.N. Routray has been entrusted with the task of conducting a ACS/HF Registry in the states of Orissa, Bihar, Jharkhand and West Bengal.

The CSI participated in both ACC and ESC annual meetings at Washington DC and Barcelona in the year 2017 and the presentations were well appreciated.

Many more new things are in the pipeline and you will see a very hard working CSI that is focused on research and academics and publications.

Best wishes to all of you.

Dr. K. Sarat ChandraPresident CSI

Message from President, CSI


Dear Colleague,

A very warm thanks for electing me as President Elect of CSI.

With the dawn of New Year, it is indeed my great pleasure to invite you to the 70th Annual Conference of the Cardiological Society of India (CSICON 2018), to be held at MMRDA Exhibition Ground, BKC Road, Mumbai -400051, India from 22nd – 25th November, 2018.

The preparation of this four-day scientific extravaganza is in full swing. This time we envisage a unique scientific program which will not only enrich the cardiologist but will also help the physician to enhance their knowledge and skill.

India is a land of diversity and the city of Mumbai presents a splendid blend of modernity and traditional culture. Our endeavour is to provide a comprehensive and memorable scientific program to address the needs of this diverse country.

The theme of the conference, “Translating Recent Advances to Regional Needs”, strives to translate advances in scientific knowledge into meaningful steps that can transform patient care. The Scientific Program will be tailored to address everyday needs of the practicing cardiologist and physician, helping them enrich their knowledge. Problem based scenarios, debates, didactic lectures, recent updates in scientific guidelines, burning controversies, interesting cases and sessions on tips and tricks in cardiology will help transform cardiovascular care to the next level. The dedicated PG Training Course is being designed by experienced and renowned teachers and will be of immense value for fellows and PG students. The Quiz for Fellows and Faculty will surely stimulate your brain and heart – be there for a scintillating session! The program will also entail detailed interaction with renowned international faculties, particularly Joint Sessions with world reputed societies like AHA@CSI, ACC@CSI, ESC@CSI, WHF@CSI, etc. Our efforts to translate the content of the conference into text in Cardiology Update book will be an important document, a ready reference that encapsulates the entire curriculum and latest scientific breakthroughs and recommendations. This conference will put the spotlight back on learning and will be an academic feast as well as an effective forum for all the participants to exchange and enrich their scientific knowledge.

I am sure that the organising team of CSICON 2018 led by Prof. Satyavan Sharma and Prof. Prafulla Kerkar will be working very hard and leave no stone unturned in making the conference a memorable event.

We sincerely hope that the blend of pleasant weather, warm hospitality, vibrant scientific program and your presence will make this conference a big success.

Prof. Kewal C. GoswamiProfessor of Cardiology AIIMSPresident Elect & Chairman Scientific Committee CSICON 2018

From the Desk of President Elect CSI 2018 & Chairman Scientific Committee, CSICON 2018


As immediate Past President it gives me great pleasure to invite you to CSI 2018 to be held in Mumbai.

The annual CSI conference which has always been excitement for all of us and we have the habit of blocking our days for this year’s biggest event.

The scientific committee has repeatedly announced to make this an academically excellent meeting with latest in Cardiology, discussed at great length.

Obviously the experts from India and Overseas will contribute immensely to the subjects and elevate the slots of this conference.

So make it a point not to miss this very very important event in Mumbai this year

Cheers!!!!

Dr Shirish (M.S.) HiremathImmediate Past President - CSI

Message from Immediate Past President, CSI


Dear Friends,

As you are aware, Indian Heart Journal (IHJ) has witnessed a tremendous growth over the past few years. A world-renowned publishing platform, rapidly increasing manuscript submissions (including a sizeable proportion from outside India), rising number of citations received and the expanding family of IHJ journals, are all testimonial to the phenomenal journey IHJ has undertaken. With this background, it is really a huge honor for me to be given responsibility to manage this journal as Editor. I therefore express my deep gratitude towards the Executive Committee of the Cardiological Society of India (CSI), and in particular the President and Honorary General Secretary of CSI, for having reposed their faith in me!

Being at the helm of a leading journal such as IHJ has many advantages — foremost being the fact that one doesn’t need to scout for good quality manuscripts. However, this privilege doesn’t come without its share of challenges! Maintaining the lofty standards that IHJ has achieved now is itself an enormous challenge, let alone better it! On my part, I can only assure you that I will put in the most sincere and honest efforts to fulfill the responsibility assigned to me and I do hope that I shall be able to live up to your expectations. Of course, this huge task cannot be accomplished without the support from all of you - the esteemed Executive Committee members of CSI, Editorial Board members, and all the CSI members at large. I am fully confident I will continue to receive your unwavering support over the next one year and wish to thank you for the same! Your suggestions, guidance and constructive criticism, are all welcome!

The immediate task at hand for the Editorial Board is to ensure that the good work initiated by the previous editors is not interrupted. Not only it is our commitment to the society, our authors, readers and reviewers, it is also a necessity as we now prepare to apply for “Impact factor” for IHJ. Getting an impact factor will be a major milestone in this wonderful journey of IHJ and I am confident, with all your support, we shall soon be able to add this feather in our cap!

Kind regards,

Dr. Manish BansalInterim Editor, IHJ

From the Desk of Interim Editor - Indian Heart Journal


Dear Friends

Greetings from CSI-NIC.

Firstly accept my heartfelt thanks for giving me the opportunity to serve this August society for two year period as NIC Chairman.

I would take this as my proud privilege and will try to do my best to improve education, training and research activities on behalf of CSI-NIC.

I feel in the midst of so many meetings & challenging times it is very important for us to coordinate among various smaller Interventional meetings and bring all of them together under one broad roof of CSI-NIC. But this task will be possible if each and every member of our society feels so and actively participate in our National Prestigeous Interventional Platform – CSI-NIC Conference which will be held from May 11th to 13th at HICC, Hyderabad.

On training front we wish to develop various Micro fellowships in niche procedures in Interventional Cardiology where we plan to exchange fellows in cardiology and junior Cardiologists for better exposure and training so that they can become better Interventional Cardiologists with improved skill set which in turn helps in managing patients in day to day life well. We request all high volume centres to volunteer for this purpose and young budding Cardiologists to write to us expressing their interest in which specialised areas they would like to get trained. We will try for some Industry support to facilitate this process.

We on behalf of CSI-NIC in cooperation with Facts Foundation, India & CRF, USA are planning to develop a world class training and new device testing facility near Hyderabad with all necessary animal lab, simulators and VAR facilities for fellows to get hands on for new Cath lab procedures like IVUS/OCT, Rotablation, etc. We would like to get this incorporated in training curriculum of all our DM/DNB training fellows so as to have exposure to these new important areas of Interventional Cardiology.

On research front we would like to plan original research protocols - MC trials to be run through CSI-NIC – the details of which were sent earlier and can be accessed on our website (wwwcsinic.com). We request the interested sites to contact us through mail - [email protected]

We would like to improve our data submissions to NIC registry by launching a simple and easy online reporting day to day reporting format by using which all regular reporting of all procedures to patients also could happen. This we feel will go a long way in accurate reporting of our data and thus indirectly helps us to get world class data for research and other purposes. We request all doctors & hospitals to encourage the online data system for day to day reporting and data submission. For all those who are not very Net savvy and can’t do this we will also continue traditional data collection at the end of the year like in earlier years.

Message from Chairman, CSI-NIC


We now request all of you to send interesting case CDs, topics for discussion during our upcoming CSI-NIC Conference to be held at HICC, Hyderabad from May 11th to13th, 2018. Please block your dates and be part of this Academic Extravaganza along with life time experiences of live cases and procedures on Asia Pacific’s largest screen which is possible only at HICC, Hyderabad in most advanced and high tech 360 degree projection platforms.

Thanking you all once again,

Sincerely,

Dr. A. Sreenivas KumarM.D., D.M., FACC Chairman, CSI-NIC, INDIA

9CSI Newsletter CSI Newsletter Volume I : No. 1 | March 2018

Dear colleagues,

It gives me immense pleasure to greet you all and on behalf of the Organising Committee we are honored to invite you to our upcoming “Mid-Term National Interventional Council” - which is going to be held on 11th to 13th May, 2018 at the Hyderabad International Convention Centre (HICC) - Novotel, High Tech city, Hyderabad.

CSI being the oldest and most prestigious organization of Cardiologists in the country and NIC is the Interventional faction of the Cardiological Society of India (CSI) has gained strength from all over the world. Every year there is a phenomenal response from the attendees and this year’s 3 days’ scientific program will make an update on the most advanced issues of complex coronary interventions as

• Optimization of PCI, Left main, Bifurcation, CTO Intervention, MV PCI and TAVR, etc.

• The Course will present interesting live-cases with discussions.

• Hands - on session for young interventional cardiologists on Rota, OCT, IVUS.

The invited faculty comprises of eminent experts in the field coming from various parts of India and abroad. We hope that this conference will provide a platform and benefit many Interventional Cardiologists to update their knowledge and learn new technique in the field of Intervention.

More than 2000 participants are expected to attend the meeting.

Once again we welcome you all and will ensure your participation becomes a memorable event.

Dr. Sridhar KasturiMD., DM, FACC, FSCAI, FESCOrg. Secretary, CSI – NIC-2018

From the Desk of Organising Secretary, CSI – NIC 2018

Dear colleagues, It gives me an immense pleasure to greet you all and On behalf of the Organizing Committee we are honored to Invite you to our upcoming “ Mid- Term National Interventional Council - which is going to be held on 11th to 13 May, 2018 at the Hyderabad International Convention Centre (HICC) - Novotel, High Tech city, Hyderabad CSI being the oldest & most Prestigious organization of Cardiologists in the country and NIC is the Interventional faction of the Cardiological Society of India (CSI) has gained strength from all over the world. Every year there is a phenomenal response from the attendees and this year’s 3 days scientific program will make an update on the most advanced issues of complex coronary interventions as

• Optimization of PCI, Left main, Bifurcation, CTO Intervention, MV PCI and TAVR ..etc. • The Course will present interesting live-cases with discussions. • Hands - on session for for young interventional cardiologists on Rota, OCT, IVUS.

The invited faculty comprises of eminent experts in the field coming from various parts of India and abroad. We hope that this conference will provide a platform and benefit many Interventional Cardiologists to update their knowledge and learn new technique in the field of Intervention. Around 1200 participants are expected to attend the course. Once again we welcome you all and will ensure your participation becomes a memorable event.

Dr. Sridhar Kasturi

MD., DM, FACC, FSCAI, FESC HOD - Sunshine Heart Institute, Secunderabad Org. Secretary, CSI – NIC-2018

From the Desk of Organizing Secretary, CSI – NIC 2018. Dr Sridhar Kasturi


We, Mumbaikars, are honoured and immensely pleased to invite you to the 70th Annual Conference of CSI. The biggest and the most comprehensive cardiology meeting in India will be held at the salubrious MMRDA grounds, Bandra-Kurla Complex from 22nd to 25th November, 2018. Set in maximum city’s swanky new business district, the venue offers space on an unprecedented scale befitting cardiology’s grandest academic fiesta. Herein you will participate in the latest science and cutting-edge research, and actively usher in new frontiers in cardiology. Combine this with easy access to the old-world charm of South Mumbai and the happening suburbs of Bandra straddled by the Bandra-Worli Sea-Link and you are guaranteed a truly unforgettable experience.

We welcome you to this most awaited annual event of the cardiology fraternity. Let us together embark upon The Link to Progress!

Dr Prafulla Gopinath Kerkar

Message from Organising Secretary70th Annual Conference of CSI, 2018


“A book is a version of the world.” — Salman Rushdie

Though there is no dearth of textbooks on cardiology, an unmet need persisted so long for a textbook that is representative of this part of the world, i.e., India. The “CSI Textbook of Cardiology - The Indian Perspective” fills this void in the market for a comprehensive textbook of cardiovascular medicine based on Indian data. In recent decades, India has been on the global focus for steadily progressing to become the “world capital of cardiovascular epidemic” on one hand and developing a market larger than the European Union together for cardiac drugs and devices on the other. This obviously kindled the interest of the world for

epidemiological and clinical data, current practices and lacunae in health care delivery, as well as results of indigenous research and drug or device trials from India. Although innumerable original articles do exist in scores of journals and a plethora of excellent monograms are also readily available, this present textbook published on behalf of CSI is the first serious attempt to bring these diverse pieces of information under one comprehensive umbrella.

The book has 85 chapters covering virtually all aspects of cardiology including topics of special interest pertaining to Indian subcontinent, which were contributed by as many as 142 cardiologists from all over India. Each of these chapters includes a detailed elaboration of available Indian data. High quality photographs are included to illustrate and reinforce textual information. As it is still relevant in Indian scenario, special emphasis has been put on clinical cardiology and rheumatic heart diseases. All aspects of coronary artery disease including the complex interventions that are being performed at different Indian centers with comparable result as the West have been detailed in this textbook. Diseases like Takayasus arteritis and tuberculosis have been given their due importance. Preventive aspects are also dealt with at great depth.

I sincerely hope this textbook would be useful to students, interns, residents, general practitioners, and specialists in the discipline of Cardiology.

Dr. Pradip Kumar DebEditor-in-Chief

Text Book Review


DYSLIPIDEMIA

• Low density lipoprotein (LDL) cholesterol: Causal role of high LDL cholesterol for ASCVD was clearly documented using large meta-analysis of over 200 prospective cohort studies. (Ference et al, EHJ 2017; 38:2459-72). FOURIER was a landmark trial with PCSK9 inhibition (Evolocumab) which reduced LDL cholesterol by 59% and consequently reduced ASCVD events by 15% (absolute risk reduction 1.5%) and MI by 27% (absolute risk reduction 1.2%) without any safety concerns including cognitive decline (EBBINGHAUS sub-study of FOURIER). PCSK9 production with small interfering RNA (Inclisiran) reduced LDL-cholesterol by 36-53% with a dose every 3 or 6 months (Ray KK, N. Engl J Med 2017; 376:1430-1440).

• Triglycerides and remnants: Genetic evidence that triglyceride-rich lipoproteins and remnant cholesterol represent an independent cause of ASCVD beyond LDL-cholesterol is gaining strength. (Nordestgaard BG. Cir Res 2016; 118:547-563). Three large randomized double-blind ASCVD endpoint trials of triglyceride-lowering with omega-3 fatty acids or pemafibrate in individuals already on a statin are ongoing (REDUCE-IT, STRENGTH AND PROMINENT).

• High-density lipoprotein (HDL) cholesterol: Recent REVEAL HPS-3/TIMI-55 study observed 9% less ASCVD (absolute risk reduction 1.0%) coinciding with 104% higher HDL-cholesterol, a reduction in apolipoprotein B containing lipoproteins more likely explains the beneficial effects as also supported by a genetic Mendelian randomization study. None of the CETP inhibitors will be available for clinical practice. Moreover, two Copenhagen prospective population-based studies demonstrated that men and women in the general population with extreme high HDL cholesterol paradoxically have high all-cause mortality (Madsen et al EHJ 2017;38:2478-2486).

• In a departure from the 2013, guidelines issued by two major societies the AACE/ACE have brought back LDL targets (https://www.aace.com/files/lipid-guidelines.pdf ).The guideline writing committee sought to incentivize treatment goals for patients. It was also notable for the introduction of the “extreme risk” group expected to achieve LDL targets lower than 55 mg/dl, non-HDL <80 mg/dl and ApoB <70 mg/dl. The groups and targets are as mentioned below. The risk was calculated based on Framingham Risk Scoring method.

Group Definition LDL target

non-HDL

ApoB target

Extreme high risk

Progressive ASCVD, UA CVD DM, CKD III & IV, HeFH Premature ASCVD

<55 <80 <70

Very High Risk

Recent ACS, DM or CKD III & IV, HeFH

<70 <80 <80

High Risk 2 or more risk factors and 10 yr risk of 10-20%

<100 <130 <90

Moderate Risk

2 or more risk factors or 10 yr risk <10%

<100 <130 <90

Low Risk 0 risk factors <130 <160 NA

Legend: ASCVD: AtheroSclerotic Cardio Vascular Disease; UA: Unstable Angina; DM: Diabetes Mellitus; CKD: Chronic Kidney Disease; HeFH: Hereditary Familial Hypercholesterolemia

HEART FAILURE

In 2017 ACC/AHA/HFSA jointly presented the Focused Update Guideline for the management of heart failure (Yancy CW et al). It focuses on optimizing pharmacotherapy and bringing most of our heart failure patients under the ambit of guideline directed medical therapy. The following points are worth mentioning:

• Apart from using natriuretic peptides for diagnosing and prognosticating heart failure patients it can also be used as a part of screening in patients at high risk of developing heart failure. This is in line with the concept of prevention being better than cure. (Heulsmann M. et al PONTIAC trial JACC 2013)

• The combination of ACEI/ARB/ARNI+Beta blockers+MRA remains the combination of choice to reduce mortality in patients of chronic heart

The Year in Cardiology: 2017Dr Ayan Kar, Prof (Dr) Soumitra Kumar


failure with reduced ejection fraction (JJ Atherton et al ESC guidelines on Heart Failure 2016).

• ARNI can be initiated in patient of HFrEF in NYHA II-III. The only caveats here being that it should not be concomitantly started on patients taking ACEI and having a history of angioedema.(McMurray et al, PARADIGM-HF trial NEJM, Sept 2014)

• Ivabradine is indicated in patients of symptomatic chronic heart failure (LVEF<35%) in NYHA II & III despite GDMT (including a maximally tolerated dose of beta blocker) and mainting sinus rhythm >70bpm (Swedberg et al SHIFT trial, Lancet Aug 2010). It has been shown to reduce heart failure admissions.

• HFpEF continues to be difficult to treat. In selected patients of HFpEF with elevated BNPs, history of hospital admission in the past 1 year, eGFR>30ml/min, creatinine <2.5mg/dl and potassium<5.0 mEq/l MRAs might help in reduction of rate of hospitalizations. Interestingly, in both TOPCAT and I-PRESERVE trials, treatment was more effective in patients with lower natriuretic peptide levels. MRAs should be reassessed in a large well-designed trials in patients with both HFpEF and HFmrEF.

• Routine use of vasodilator therapy in HFpEF with nitrateS and phosphodiesterase inhibitors have been shown to be ineffective.

• Heart failure patients with iron deficiency anemia and in NYHA II & III (ferritin <100 ng/ml and trasferrin saturation <20%) have better symptom relief and quality of life with intravenous iron.

• Patients at risk of heart failure and on therapy for chronic heart failure are required to attain a target SBP<130 mm of Hg with GDMT.

• In patients of heart failure with obstructive sleep apnea, judicious use of CPAP results in reduction of daytime somnolence and better quality of life (McEvoy RD et al, SAVE trial NEJM September 2016).

• Currently, drugs recommended in HFrEF are not recommended in HFmrEF, but data from beta-blocker trials and CHARM suggest that they may be effective and novel pragmatic trials should put this hypothesis to test.

• In CASTLE-AF, catheter ablation in patients with HFrEF (EF<35%) and paroxysmal or persistent AF appeared to reduce combined HF hospitalization and all-cause mortality (Marrouche N Fea et al presented at ESC 2017).

• Intravenous iron was shown to reduce HF hospitalization and improve 6MWT and quality of life in a meta-analysis (Anker SD et al Eur J Heart Fail doi 10 1002/ehjf 823). Oral iron therapy in IRONOUT-HF trial did not have similar success.

• Ularitide in TRUE-AHF trial and Serelaxin in RELAX-AHF2 were negative trials. In BLAST-AHF, a biased ligand of the angiotension II type 1 receptor did not reduce dyspnea, worsening HF and hospital length of stay. Thus, by end of 2017 several interventional strategies in acute heart failure (continuous diuretic infusion, ultrafiltration, vasodilators and inotropes) have failed.

• In COSMIC-HF, a phase II trial with Omecamtiv Mecarbil, a new myosin activator, cardiac function was found to improve along with lowering of NT-proBNP. (Teerlink et al Lancet 2016;388:2895-2903). A phase III trials is ongoing.

• Although stem cell therapy has generally proved disappointing, but in REGENERATE-IHD and CHART-1, intramyocardial injection of autologous bone-marrow derived cells in ischemic cardiomyopathy appeared safe and improved EF, NYHA class, NTProBNP etc. (Chowdhury T et al. Eur J Heart Fail 2017; 19:138-147; Bartunek et al. Eur Heart J 2017; 38:648-660).

• In 2016, DANISH trial demonstrated no overall benefit of primary prophylactic ICD implantation in 556 patients with non-ischemic


cardiomyopathy. A recent meta-analysis of 8567 patients, primary prevention ICD implantation reduced all-cause mortality both in patients with and without ischemic heart disease by 24% (Shun-Shin MJ et al EHJ 2017;38:1738-1746). Is the question answered then? By far not.

HYPERTENSION

• With the publication of the SPRINT data (SPRINT Research Group Nov 2015 NEJM), the ACC and AHA were prompt to change the guideline on treating hypertension. The concept of pre-hypertension is now obsolete and replaced by TWO groups: a) elevated BP AND b) Stage I hypertension.

The new classification has seen significant uproar amongst clinicians as it brings a larger size of the population under the ambit of contemporary antihypertensive regimens.

• Clinicians and cardiologists treating CKD patients and those who are post renal transplant need to attain target blood pressure of ≤ 130/80 mm of Hg.

• In adults with hypertension primary aldosteronism should be suspected in patients with the following concurrent problems: resistant hypertension/adrenal masses/early onset hypertension and family history of hypertension/ Stroke in Young (<40 years).

• White coat hypertension and masked hypertension mandate the use of 24 hr Ambulatory BP monitoring.

• Patients at risk of heart failure, HFrEF, or with chronic kidney disease or post renal transplant status should have blood pressure targets less than 130/80 mm of Hg.

• Elderly with an age in excess of 60 years need initiation of anti-hypertensives if the SBP>150 mm of Hg with targets set at below 140 mm of


Hg for those with high CVD risk or past history of CVA.

• SPYRAL HTN-OFF MED trial (Townsend RR et al. Lancet 2017; 390:2160-2170) included drug-naïve or drug-discontinued hypertension patients who were subjected in a blinded design (with a sham-procedure) to more extensive and more distal denervation of renal-arteries. Despite some success (Office SBP decreased by 10 mmHg and ABPM-BP decreased by 6 mmHg without major adverse events), results should be interpreted cautiously in light of the prior failures in the field.

VALVULAR HEART DISEASE

a) Ischemic Mitral Regurgitation

• Ischemic Severe MR remains a difficult to treat subset. In light of recent clinical evidence and publication of 2 major trials on Ischemic MR, the American Association for thoracic surgery has changed its recommendation (Kron IL et al. The Journal of Thoracic and Cardiovascular Surgery, 2017 May). The trials showed that more than half of alive patients with mitral valve repair developed recurrence of mitral regurgitation accompanied by refractory heart failure and frequent hospitalizations. Thus the current guidelines emphasizes:

A. Mitral valve replacement is considered as a reasonable option in patients of severe MR who are symptomatic despite optimal medical and cardiac device therapy, dilated LV cavity(LVIDD>6.5cm), significant leaflet tethering and basal aneurysm/dyskinesis.

B. Mitral valve repair with an undersized rigid annuloplasty ring is considered a reasonable option in the same group of patients as above but without significant left ventricular enlargement, significant leaflet tethering or basal aneurysm or dyskinesis.

b) Transcatheter Mitral Valve repair or replacement

Transcatheter MV repair dominated by Mitra-clip system for symptomatic, severe functional, degenerative or mixed MR has been reported. While the transcatheter MV repair has been shown to reduce heart failure symptoms, further research (COAPT, French MITRA-FR, RESHAPE-HF2, MATTERHORN are ongoing studies) is needed on procedural and long-term clinical outcomes (Praz F et al. Lancet 2007;390:773-780).

Transcatheter MV implantation in failed degenerated surgical MV prostheses (Valve-in-valve) and failed annuloplasty rings (Valve-in-ring) has had overall acceptable technical (92,3%) and device (85.5%) success rates in multicenter registry. (Yoon SH et al JACC 2007; 70:1121-1131). In a recent report of transcatheter MV implantation on 30 patients with primary functional MR and high surgical risk, transapical implantation of the tendyne valve, was successful in 28 patients with no acute deaths. (Muller D WM JAC 2017; 69:381-391).

c) TAVI : With rapid adaptation of TAVI in patients with AS and high surgical risk, role of TAVI in patients at low risk of surgery and younger patients is currently being explored. These trials may also add an important information on longevity of bioprosthetic aortic valves.

TAVI for non-calcified native aortic valve regurgitation has been challenging with prosthesis embolization and high rate of paravalvular leakage. Newer generation TAVI systems have improved the scenario with fewer patients requiring a second valve (10%) and having significant residual AR (3%) (Sawaya et al. JACC Cardiovasc. Interv. 2017; 10:1048-1056).

d) Tricuspid regurgitation: Percutaneous transcatheter TV therapy is an evolving treatment option for significant TR who are not candidates for open heart surgery. Mitra-clip system was successfully implanted in TV in 97% of the cases with reduction in TR by at least one grade and no intraprocedural deaths (Nickenig et al Circulation 2017; 135:1802-1814).


ACUTE CORONARY SYNDROMES

• Where thrombolysis is the revascularization strategy of choice, the time duration for initiation of therapy has been shortened to 10 mins from 30 mins.(Borja Ibanez, Stefan James ESC guidelines on STEMI 2017).

• New onset left and right bundle branch block are now considered equal for recommending urgent angiography, in the background of ischemic symptoms.

• The choice of vascular access in primary angioplasty should be radial to reduce bleeding risk to the patient. (Valgimigli M et al, MATRIX trial, Lancet June 2015).

• Immediate angiography for resuscitated out-of-hospital cardiac arrest in STEMI patients.

• Risk score stratification for NSTEMI patients to dictate the appropriate strategy (invasive versus ischemic-guided) and the timing of the strategy (early versus late invasive) in patients with NSTEMI.

• Early invasive strategy (within 12 hours) in high-risk NSTEMI patients. (TAO trial post-hoc analysis, Deharo et al; Circulation 2017; 136:11895-1907).

• Routine thrombus aspiration is no longer recommended,(TOTAL and TASTE trials).

• Bivaluridin has been downgraded from Class I to IIa and LMWH has been upgraded from IIb to IIa.

• Drug eluting stents have been upgraded to a Class I recommendation & Bioresorbable scaffolds have been officially withdrawn from the market.

• Therapeutic hypothermia for comatose STEMI patients with out-of-hospital cardiac arrest (AAN guideline on “Reducing brain injury after Cardiopulmonary arrest, Neurology May 2017).

• Routine use of supplemental oxygen after suspected MI was not found to influence one year mortality.

(R. Hofman et al, DETOX2-SWEDEHEART NEJM, Sep 28, 2017). The cut off for using supplemental oxygen has been reduced from 95% to 90% saturation.

• Inappropriate in-hospital use of NSAIDs (caution against the use of these drugs after AMI).

• Inappropriate prescription of prasugrel at discharge in patients with a history of prior stroke or TIA (caution against the use of prasugrel in patients with prior TIA/stroke, because of net clinical harm in these patients. The FDA also issued a black box warning on this).

• Inappropriate prescription of high-dose aspirin with ticagrelor at discharge (caution against the use of high-dose aspirin >100 mg among patients receiving ticagrelor. The FDA also issued a black box warning on this).

• For STEMI patients without cardiogenic shock, complete revascularization, in particular using a staged approach, has been confirmed to be beneficial in a recent observational study (Iqbal MB et al JACC Cardiovasc. Interv 2017; 10:11-23) and in a recent meta-analysis. (Elgendy et al. JACC Cardiovasc. Interv 2017; 10:315-324). In contrast for STEMI patients with cardiogenic shock, the pendulum has swung in the opposite direction. This is because in the CULPRIT-SHOCK trial (Thiele H et al. N. Engl J Med 2017; doi 10 1056/NEJ Moa 1710 261), primary composite end-point of death or renal failure leading to renal replacement therapy occurred more often in the multi vessel PCI group than in the culprit lesion only PCI group (p=0.01). The difference was mainly driven by lower all-cause mortality in the culprit lesion only PCI group.

• Another trial in STEMI patients (Smits et al. N Engl J Med 2017; 376:1234-1244) suggests that FFR is feasible in acute STEMI patients and reduces later revascularization procedures; however values obtained with FFR in acute setting could be influenced by underlying vascular changes.


DUAL ANTIPLATELET THERAPY FOR CAD

• Personalized therapy is advocated weighing ischemic vs bleeding risk. The risk of bleeding is proportional to the burden of DAPT and its duration. The benefits of prolonged DAPT is more in patients presenting with ACS than with stable angina.

• For ACS patients, the default DAPT duration should be 12 months (Mauri L et al DAPT trial, NEJM 2014), irrespective of the revascularization strategy (medical therapy, PCI, or CABG surgery)

• Clopidogrel is recommended as the default P2Y12 inhibitor in patients with stable CAD treated with PCI, patients with an indication for oral anticoagulation, and ACS patients in whom ticagrelor or prasugrel are contraindicated. Ticagrelor or prasugrel is recommended for ACS patients unless there are drug-specific contraindications.

• Six months of DAPT should be considered in patients at high bleeding risk (PRECISE-DAPT score ≥ 25). Therapy longer than 12 months may be considered in ACS patients who have tolerated DAPT without a bleeding complication.

• The need for a short DAPT regimen should no longer justify the use of bare-metal stents instead of newer-generation drug-eluting stents, rather it should be decided based on the patients’ ischemic risk and procedural details(e.g. dedicated bifurcation disease, left main stenting, poor LV function, long segment stenting, or history of ISR).

• Trials with early de-escalation of antiplatelet treatment (TROPICAL-ACS trial: Prasugrel to Clopidogrel monitored by Platelet function testing and TOPIC trial: Ticagrelor to Clopidogrel without platelet function testing) appeared safe considering reduced bleeding events. However the efficacy regarding ischemic events remains to be proven.

•

NEUROPROTECTION AFTER ACS

• For patients who are comatose in whom the initial cardiac rhythm is either pulseless ventricular tachycardia (VT) or ventricular fibrillation (VF) after out-of-hospital cardiac arrest (OHCA), therapeutic hypothermia (TH; 32-34°C for 24 hour) is highly likely to be effective in improving functional neurologic outcome and survival compared with non-TH and should be offered. (Geocadin RG et al. Practice guidelines summary: Reducing brain injury following cardiopulmonary resuscitation. Neurology. May 30, 2017).

• For patients who are comatose in whom the initial cardiac rhythm is either VT/VF or asystole/pulseless electrical activity (PEA) after OHCA, targeted temperature management (36°C for 24 hour, followed by 8 hour of rewarming to 37°C, and temperature maintenance below 37.5oC until 72 hour) is likely as effective as TH and is an acceptable alternative.

• On those same lines pre-hospital therapeutic hypothermia has been found to be ineffective and hence should not be offered.

CORONARY INTERVENTIONS

• A large number of articles were published in 2017 which enhanced our understanding of coronary interventions and accordingly refined our treatment strategies without major changes. Newer-generation DESs continued to maintain consistent results with regard to long-term safety (COMPARE II, DUTCH PEERS trial, SORT OUT VI & VII trials).

• Heparin was shown to be as effective as bivalirudin in STEMI patients treated with PCI (Erlinge et al. N Engl J Ned 2017; 377:1132-1142).

• Major reductions in bleeding rates were found when triple therapy with warfarin, aspirin and clopidogrel was reduced to dual therapy with dabigatran and clopidogrel in patients with atrial fibrillation (Cannon CP et al. N. Engl J Med 2017;377:1513-1524).


PREVENTION

Lifestyle:

• In patients with coronary heart disease highest vs lowest variation in body weight was associated with 64% more coronary and 124% more mortality events (Bangalore S, N Engl J Med 2017, 376:1332-1340).

• Moderate alcohol intake is associated with less of most cardiovascular disease endpoints while heavy and binge drinking or alcohol abuse were associated with more CV disease or deaths (Bell S BMJ 2017; 356:909).

• Association between physical activity and mortality was strongest in those with lowest strength and lowest cardiorespiratory fitness suggesting that these subgroups would benefit the most from physical activity. (Celis-Morales CAEHJ 2017;38:116-122).

• Worldwide ambient air pollution with aerodynamic diameter <2.5 mm was the fifth-ranked mortality factor in 2015 and has gained in importance over 25 years. (Cohen AJ Lancet 2017; 389:1907-1918).

Inflammation: In the CANTOS trial, 10061 patients with previous MI and CRP ≥ 2 mg/L despite use of aggressive secondary prevention strategies were subjected to anti-inflammatory therapy with canakunimab which targets IL-1b. ASCVD was reduced by 14%, total cancer mortality by 51% and lung cancer by 67% with small absolute increase in fatal sepsis. This implies a narrow therapeutic window for such an anti-inflammatory approach (Ridker PM et al N Engl J Med 2017; 377:1119-1131).

Diabetes:

• After EMPA-REG trial (with Empaglifozin), Canaglifozin in CANVAS trial was shown to reduce CV complications, kidney disease and death beyond glycemic control in 10142 patients with Type 2 Diabetes with high CV risk. (Neal B et al. N Engl J Med 2017;377-657). In CANVAS-

Renal trial, canaglifozin also lowered progression of albuminuria and loss of kidney function.

• Liraglutide, a glucagon like peptide 1 (GLP) receptor agonist, has reduced not only ASCVD but also development and progression of diabetic kidney disease (Marso SP et al, N Engl J Med 2017;377:644-657).

• CVD-REAL, a large observational study of Type 2 Diabetes patients of 15% with and 85% without established ASCVD found that SGLT-2 inhibitors as a drug class was associated with a lower risk of heart failure and all-cause mortality (Kosiborod M et al. Circulation 2017;136:249-259).

• EXSCEL trial with Exenatide (GLP-1 receptor agonist) was a negative trial in terms of reduction of ASCVD events. (Hypertension and dyslipidemia have been discussed separately).

ARTERIAL AND VENOUS THROMBOSIS

In the COMPASS trial, 27395 patients with stable atherosclerotic vascular disease to receive rivaroxaban plus aspirin, rivaroxaban alone or aspirin alone. (Eikelboom JW et al N Engl J Med 2017;377:1319-1330). The study was prematurely stopped due to 24% fewer ASCVD events (absolute risk reduction 1.3%) and 18% fewer deaths; however this was at the cost of 70% increased major bleeds (absolute risk increase 1.2%). In the COMPASS subgroup of 27% with chronic peripheral arterial disease, rivaroxaban plus aspirin vs aspirin alone reduced amputations.

IMAGING

• Left ventricular GLS (Global longitudinal strain) measurement by echocardiography has better inter-observer agreement than LVEF for follow-up of LV systolic function by multiple observers. (Negishi T et al. JACC Cardiovasc Imaging 2017; 10:518-522).


• 18F-flurodeoxyglucose PET has become one of the standard imaging tests in patients with suspected endocarditis (Habib G et al. EHJ 2015; 36:3075-3128).

• Multi-parametric CMR can characterize complex physiological processes in vivo. These include semi-quantitative myocardial perfusion reserve index, blood-oxygen level-dependent imaging which measures myocardial oxygenation and MR-spectroscopy of phosphocreatine to adenosine tri-phosphate (PCr/ATP) ratio to study myocardial energy handling. (Levelt et al. EHJ 2016; 37:3461-3469).

• Cardiac CT imaging can play an important role in follow-up of TAVI. ‘Hypo-attenuated leaflet thickening’ (HALT) and ‘Hypo-attenuation

affecting motion’ (HAM) are important findings in both transcatheter and surgically implanted aortic bioprosthetic valves which can guide personalized anticoagulation treatment (Bax JJ, EHJ 2017; 38:2208-2210).

• Majority of the literature reports on hybrid imaging, mostly with PET and CT, but also with PET and CMR. These can play important role in diseases like sarcoidosis, endocarditis etc. New mode of hybrid imaging includes SPECT or PET perfusion imaging and CCTA fused on dedicated workstation. Further studies are required on role of this hybrid imaging in detection of significant CAD, avoiding unnecessary invasive coronary angiography and interventions (Liga R et al. EHJ Cadiovasc Imaging 2016; 17:951-960).


Members willing to present their papers in the Scientific Sessions of the 70th Annual Conference of the Cardiological Society of India (CSI) to be held from 22nd November to 25th November 2018 at Mumbai, are requested to send the abstracts to Dr. Kewal C Goswami, President-Elect, CSI and Chairman, Scientific Committee 2018 of 70th Annual Conference of CSI, 2018, E-mail : [email protected] on or before 30th June 2018 midnight. The Chairman, Scientific Committee will also communicate this information to all the members along with the prescribed abstract form for submission of short papers for oral/poster presentation.

ORATIONS:

The Hony. General Secretary invites recommendations on the following.

1. Smt. Uma Rani Banerjea Memorial Oration (This Oration shall deal with any aspect of Ischemic Heart Disease)

2. Dr. Amalananda Das Memorial Lecture

3. Dr. V. V. Shah Oration (NSPHERE Oration)

4. Dr. K K Datey Memorial Oration (Sponsored by Sun Pharmaceuticals)

Recommendation should be sent to the Hony.General Secretary, Cardiological Society of India about the prospective candidate with six copies of bio-data and list of publication for consideration by the Special Committee dealing with Oration, Lectures and Awards. The Minimum Criteria for Selection of Oration are as under:

i. The nominee must be a member of CSI for minimum continuous period of 5 years. He must be of Indian origin and have worked in India.

ii. Must have had Academic/Research experience of not less than 5 years.

iii. He must have a total of at least 15 publications in the field of Cardiology, in journal of repute and also Indian Journals.

5. The proposer must submit a written proposal seconded by another member.

6. The proposal must be accompanied by –

i. Complete Bio-data.

ii. List of publications as the first author.

iii. List of publications as the joint author.

iv. Three of the best publications.

v. Title/Titles of subjects on which the nominee is likely to speak. Copies of items 4 and 5 (4 -5) must be submitted.

7. The person who has received one oration will not be considered for any other orations but can be considered after 5 years for another oration.

AWARDS: (APPLICABLE ONLY TO THE MEMBERS OF THE CSI)

a) Prof. D.P. Basu Memorial Award.

b) Travel Award (CSI).

c) Modi Mundi Pharma Award.

d) Navin C Nanda Young Investigator Award.

Conditions for Awards:

a) Prof. D.P. Basu Memorial Award – Age of the candidate must be below 45 years.

b) CSI Travel Award – This award is applicable to the members of the CSI who are currently undergoing postgraduate training in Cardiology. Their age must be 35 years and below.

These papers should have been accepted for presentation at the annual conference of the CSI.

c) For Modi Mundi Pharma Award – The Nominee must be a member of CSI for a minimum continuous period of five years. He must be of Indian origin and have worked in India.

He must have Academic / Research experience of not less than five years.

A Notice for all the Members of The CSI


Age of the candidate must be below 40 years.

Minimum publication of 3 (three) in index journals.

d) Navin C Nanda Young Investigator Award -

• The award is applicable to members of CSI of Indian origin.

• This award pertains to the field of echocardiography and the session will be held during the Echocardiography CME progamme on the first day of the Annual Conference of Cardiological Society of India.

• The award is restricted to individuals below the age of 40 years or 5 years after eligible Qualification whichever is less.

• The paper submitted should be an original work that has neither been presented elsewhere, nor sent for publication in any journal. This will be certified by the principal investigator and endorsed by the Head of the Department.

• The candidates should send a brief CV, including prizes, medals or other awards along with the papers.

• The candidate will not be eligible to compete for any other award in the same year.

Five copies of the full article should be submitted to Dr. Kewal C Goswami, President-Elect.- CSI and Chairman, Scientific Committee 2018 of 70th Annual Conference of CSI, 2018, E-mail : [email protected]. The article must be submitted on or before 31st August, 2018.

• The selected speakers will be informed about their papers by 30th September, 2018.

• If no paper is found to be as per standard then no award will be given.

Candidates should apply for awards in the following proforma duly certified by the Head of the Department of the Institution. (I) Name, (ii) Age, (iii) Address, (iv) Qualification, (v) Present Occupation, (vi) Appointment held, (vii) Prizes,

Medals and other awards, (viii) Papers presented or published, (ix) Comments and counter signature of the Head of the Department of the institution and a certificate from the Head of the Dept - that the candidate is the principal worker in the Project.

For ALL AWARDS – The candidate should submit 6 (six) copies of full papers to Dr. Kewal C Goswami, President-Elect.- CSI and Chairman, Scientific Committee 2018 of 70th Annual Conference of CSI, 2018, E-mail : [email protected] on or before 30th June 2018, that these papers are to be considered for the Award Session. These papers must be submitted on or before 30th June 2018.The selected speakers will be informed in due course.

For CSI TRAVEL AWARD – The Award Committee will decide on the merits of the papers and the work done by the candidate for the selection of the Award. Abstract should be sent to Dr. Kewal C Goswami, President-Elect.- CSI and Chairman, Scientific Committee 2018 of 70th Annual Conference of CSI, 2018, E-mail : [email protected] on or before 30th June 2018 for acceptance but simultaneously they will also have to submit 4 copies of the full papers to the Award Committee. A candidate will not be eligible to compete for more than one award in the same year. If the papers are found substandard then NO AWARD WILL BE GIVEN.

Dr. Soumitra Kumar Hony. General Secretary, CSI

N.B.: The abstract details are downloadable from the scientific committee website: www.csicon2018.com and must be submitted only at this website.

Contact for Abstracts: Dr. Kewal C GoswamiPresident Elect-CSI & Chairman Scientific Committee 2018, 70th Annual Conference of CSI

Dr. Nitish Naik (Joint Secretary)E-mail: [email protected]


CSI-NIC Mid-Term Meet 2018National Interventional CouncilCardiological Society of India

11th to 13 May, 2018 at the Hyderabad International ConventionCentre ( HICC ) - Novotel , High Tech City , Hyderabad.

REGISTRATION FORM

Please fill the form in CAPITAL LETTERS

Details

Name:______________________________________Title/Position:______________________________

Department/Hospital:___________________________________________________________________

Address:______________________________________________________________________________

_____________________________________________________________________________________

City: ____________________ Country: ___________________ Pincode: __________________________

Email:________________________________________________________________________________

Mobile: ________________________________

CSI Membership Number: _______________________________________________________________

Please tick the appropriate box.

Registration Fees Structure

Category Till 15th March 2018 After 15th March 2018 Spot Registration

□ CSI Life Members Free Free INR 20,000

□ Fellow / PG Students INR 4,000 INR 6,000 INR 15,000

□ Non-CSI Members INR 11,000 INR 17,000 INR 20,000

□ Technologists / Nurses INR 6,000 INR 12,000 INR 15,000

□ Industry INR 15,000 INR 25,000 INR 30,000

□ Accompanying Person INR 11,000 INR 17,000 INR 20,000

Important Dates for Registration:

Till 15th March 2018 – Early Bird Registration

After 15th March 2018 – Regular Registration

20th April – Online Registration Closes

After 20th April – Spot Registration


• Registration mode will be both online and offline.• Registration is mandatory to attend the Conference• No Cheque will be accepted.• Accompanying persons & children will not be allowed to the scientific sessions• For on Spot registrants, delegate kit may will be subject to availability.• Hotel accommodation will not be provided for on spot registration.• For Spot Registrations: Only Cash / Card Swipe will be accepted• Spouse accompanying will be charged as accompanying person• Kit will be handed over to the registered delegate only.• After the conference, no kit, Program book, abstract book or any workshop material will be disbursed to the delegate /associate

delegate / PG Student.• The registration confirmation letter will be sent to you within 15 days after the payment is realized.• Fellow/PG Students must submit a bonafide certificate from HOD / Institute along with registration form.• Online registration will be closed on mid night, April 20, 2018. Further registration will start at the conference venue as “SPOT

Registration” category only.

On-Site Registration• Pre-registration will close at midnight April 20th, 2018. Thereafter the registration office will not be able to accept registrations

online or by phone. Any delegates wishing to register after pre-registration can register on arrival at the registration desk on May 11-13 May 2018.

• On-site registrations will be accepted, but conference kit will not be provided. Delegates planning to register on-site are advised to arrive early. On-site registration will proceed on a first-come, first-served manner.

Payment Methods• All payments for registration fees should be made in full before the conference during time of filling the registration form online

and by draft if offline. If you have any problems making the payment please contact us at [email protected]. No registration will be accepted without full payment.

Cancellation Terms and Conditions• Cancellation & refund policy-The last date for receipt of cancellation request is 1st April, 2018. The refund amount after

deduction of bank handling charges will be disbursed 30 days after the conference is over.• Offline registration will be accepted only with draft.

Certificates of AttendanceCertificates will be available for all delegates who attend the conference.

This form to be sent to:Conference Secretariat NIC 2018 FOR OFFICIAL USE:CSI-NIC 2018, HyderabadF-402, 4th Floor, Aditya Summit Received on:Veterinary Colony, Shaikpet Hyderabad, Telegana 500033Phone: +91-9959444769 / +91-9848028716 Office Reg. No.:Email: [email protected] / www.nic2018.org

Registration Guideline

Payments to be made by Demand Draft in favour of:

CSI MID TERM NIC MEET 2018Bank A/c No: 110510100187980Bank: ANDHRA BANKBranch: Banjata Hills, Hyderabad – 500 034For NEFT/RTGS Transfer: IFSC Code: ANDB0001105PAN No: AAAAC8345H

DD No. _________________________

Bank Name _________________________

Date _________________________

Signature _________________________


70thAnnual Conference of Cardiological Society of India CSICON - 2018

22nd- 25th November 2018, Mumbai

PROTOTYPE OF ONLINE ABSTRACT SUBMISSION FORM

1. Coronary Artery Disease

2. Interventional - Coronary

3. Interventional - Structural

4. Interventional - Peripheral

5. Valvular Heart Disease/RHD

6. Pediatric Cardiology

7. Pacing & Electrophysiology

8. Hypertension

9. Heart Failure

10. Cardiomyopathy

11. Echocardiography/Imaging

12. Cardiac Surgery

13. Epidemiology

14. Cardio-Diabetes

15. Miscellaneous

Abstract Submission Closes: June 30th 2018

Please Read Instructions Carefully

Before Submitting Abstracts

Abstracts Must Be Submitted Online Only

Top 10 Abstracts will be considered for Awards (Prizes: 1st - Rs. 51,000 ; 2nd – Rs. 21,000 ; 3rd - Rs. 11,000)

Abstract Category (Select one box only)

Title

First Name

Institution(s)

Abstract

Corresponding Author First Name

Designation

Address for Correspondence

Middle Name Last Name

Telephone

Email Fax

Mobile

Authors

Middle Name Last Name

Institution(s)

Institution

City


INSTRUCTIONS FOR ABSTRACT SUBMISSION

• Abstract must be submitted ONLINE ONLY. No abstract will be accepted by Email or by hard copy under any circumstances.

• In case of difficulty, contact us at [email protected]

• Abstract must be typed in English, single-spaced, using at least 9 point size font and should not exceed 2000 characters.

• Title: Do not bold, italicize or underline any items in the title field. Do not include authors and institutions in the title field. Avoid the use of abbreviations in the title field.

• Authors name should be listed as first name, middle name, last name. Name of presenting author should be filled in presenting author field only.

• Corresponding author detail must be filled in the corresponding author field only.

• Institution: List the institutions in which the work is carried out. Please do not mention individual author’s affiliations.

• Type body of the abstract in order of Background, Methods, Results and Conclusions.

• Do not include title, names and institutions in the field for abstract.

• Standard abbreviations are acceptable. Uncommon abbreviations must be put in parenthesis and preceded by the full word the first time it appears in the text.

• Tables and graphs can be included and will be considered as 600 characters each. hotographs/Images/other figures will not be accepted.

• Please proof read the abstract carefully for factual and spelling errors. The spelling of names, the order of authors and institution name of accepted abstracts will appear in Indian Heart Journal as submitted.

• The presenting author must be a registered delegate for the conference.

• Once submitted, no corrections are possible. To withdraw an abstract write to the following email address: [email protected] within 15 days of submission.

• Abstracts must be submitted online by June 30th 2018 midnight.

• The abstract details are downloadable from the scientific committee website: www.csicon2018.com & must be submitted only at this website.

• Contact for Abstracts : Dr. Kewal C. Goswami President Elect-CSI & Chairman Scientific Committee CSICON 2018 Dr. Nitish Naik (Joint Secretary) e-mail: [email protected]


REGISTRATION FORM

DELEGATE DETAILS

[ ] Mr. [ ] Mrs. [ ] Ms. [ ] Dr. [ ] Prof.

First Name: ............................................................ Middle Name: .......................................................... Last Name: .............................................................................

Name to appear on Badge � Certi�cate: ..................................................................................................................................................................................................

CSI Membership Number: .................................................................................................................................................................. Sex: [ ] Male [ ] Female

Address...................................................................................................................................................................................................................................................................

City: ............................................................................ State: ................................................................................ Pin Code: ..........................................................................

Phone: ................................................................. Mobile: ............................................................ Email: ........................................................................................................

Organisation / Institute: ..................................................................................................................................................................................................................................

Meal Preference: [ ] Vegetarian [ ] Non-Vegetarian

ACCOMPANYING PERSON DETAILS (Accompanying persons will not have access to the Scienti�c Halls.)

[ ] Mr. [ ] Mrs. [ ] Ms.

First Name: ............................................................ Middle Name: .......................................................... Last Name: .............................................................................

Age: .......................... Sex: [ ] Male [ ] Female Other Details: ...................................................................................................................................................

Meal Preference: [ ] Vegetarian [ ] Non-Vegetarian

Registration Category:

Cheque / DD No. .................................. Dated ................................... Drawn on .................................................................. Branch ....................................................

Total Amount (in words) ..................................................................................................................................................................................................................................

THPlease make payment by DD / At Par Cheque, payable at Mumbai in favour of ��0 ANNUAL CONFERENCE OF CSI 2018 MUMBAI�

Online registration facility is available on www.csi2018mumbai.com

PAYMENT DETAILS

(PLEASE FILL IN CAPITAL LETTERS)

The to Link Progress

ND TH22 - 25 NOV 2018 MMRDA GROUNDS, BANDRA-KURLA COMPLEX, MUMBAI|

th th stCategory Till 15 March, 16 March - 1 July - Spot th th 2018 30 June, 2018 7 November, 2018

[ ] CSI Member INR 7,500 INR 13,000 INR 18,000 INR 25,000

[ ] Non CSI Member INR 12,000 INR 17,000 INR 22,000 INR 30,000

[ ] Accompanying Person INR 12,000 INR 17,000 INR 22,000 INR 30,000

[ ] PG / Nurse / Technician INR 5,000 INR 6,500 INR 7,500 INR 12,000

[ ] Industry INR 16,000 INR 20,000 INR 24,000 INR 32,000

[ ] Foreign Delegates (SAARC) INR 12,000 INR 17,000 INR 22,000 INR 30,000

[ ] Foreign Delegates (Non-SAARC) USD 500 USD 800 USD 1,000 USD 1,200

Please send the duly �lled registration form along with payment to:

The Registration Secretariat, Vama Events Pvt. Ltd., Of�ce No. 4, Gr. Floor, Anmol C.H.S.,

Sakharam Keer Road, Parallel to L. J. Road, Shivaji Park, Mumbai - 400 016

Tel: + 91 22 2438 3498 | Telefax: + 91 22 2438 3499 | Email: [email protected] | Website: www.csi2018mumbai.com


Fellow FCSI 2017

Dr. Bibhash Ranjan NathKolkata

Dr. Virendra Prasad SinhaPatna

Dr Manas Kr. BanerjeeAsansol

Dr. S. ArthanariChennai

Dr. Rajesh Kumar JhaIndore


Fellow FCSI 2017

Dr. Rajeeve Kumar RajputNew Delhi

Dr. Ramesh Kumar VermaSehore, Madhya Pradesh

Dr. Saroj MandalKolkata

Dr. Manoj Kumar BansalIndore

Dr. Dipak Ranjan DasCuttack


Names and Addresses of Executive Committee Members of CSI for the year 2017-2018

Dr. K. Sarat Chandra President-CSIH.No. 564/A-33, Road No. 92Opp. Lotus Pond Jubilee Hills, Hyderabad 500 032Ph: +91 98480 12212 (M)E-mail: [email protected]

Dr. Kewal C Goswami President-Elect - CSI 4313/3 Ansari Road, Darya Ganj, New Delhi 110 002Ph: +91 98113 78890 (M)E-mail: [email protected]

Dr. M.S. HiremathImmediate Past President-CSI 1126 B, Model ColonyShivaji Nagar Pune 411016Ph: +91 98220 55440 (M)E-mail: [email protected]

Dr. Sibananda Datta Vice President-CSI5, Hem Banerjee Lane, Shibpur, Howrah 711102Ph: +91 98300 42745 (M)E-mail: [email protected]

Dr. Satyendra Tewari Vice President-CSIDepartment of Cardiology S.G.P.G.I.M.S; Lucknow, U.P. -226 014Ph: +91 94150 12127 (M)E-mail: [email protected] Dr. P.P. Mohanan Vice President-CSISopanam, Pottayil Lane Poothole, Thrissur Kerala - 680 004Ph: +91 98460 76006 (M)E-mail : drppmohanan @gmail.com

Dr. Saumitra Ray Vice President-CSI99/5/C Ballygunge Place, Kolkata -700 019Ph: +91 98300 22317(M)E-mail: [email protected]

Dr. Soumitra KumarHony. General Secretary-CSI 58/1, Ballygunge Circular Road Flat - 52B, “SAPTAPARNI’Kolkata 700 019Ph: +91 98310 32519 (M)E-mail: [email protected]

Dr. Soura MookerjeeTreasurer-CSIFlat 2/1, Taniya Apartment, 2250, Garia Place Road, GariaKolkata 700 084Ph: (033) 24285365, +91 9051363845E-mail: [email protected]

Dr. Manish BansalInterim-Editor, lndian Heart Journal-CSIDepartment of CardiologyMedanta The Medicity, Sector 38, Gurgaon, Haryana, 122 001Ph: +91 9971991749E-mail: [email protected] Dr. Arvind Kumar Pancholia Associate Editor-IHJ-CSI 11/4, North Rajmohalla, Indore 452 002Ph: +91 98270 27920 (M)E-mail: [email protected]

Dr. Praveen Chandra EC Member-CSIG-86, Saket, New Delhi - 110 017Ph: +91 98101 25370(M)E-mail: [email protected]

Dr. C. RaghuEC Member-CSI Plot 2, Maitri Vihar, Ameerpet, Hyderabad - 500 038Ph: +91 98481 5S650 (M)E-mail: [email protected]

Dr. Gurpreet Singh Wander EC Member -CSI95-B, Kitchlu Nagar Ludhiana 141 001Ph: +91 98155 45316(M)E-mail: [email protected] / [email protected]

Dr. Jabir Abdullakutty EC Member-CSIDaressauaam, MariathuruthuP.O. Kottayam Kerala-686 017Ph: +91 94470 11773 (M)E-mail: [email protected]

Dr. Brian PintoEC Member-CSI 301 Monarch, 2nd Hasnabad Road Santacruz (W), Mumbai 400 054Ph: +91 98200 54913(M)E-mail: [email protected]

Dr. Shashi Shekhar Chatterjee EC Member-CSI223-C, Road No-6BRajendra Nagar, Patna Bihar 800 016Ph: +91 94316 23969 (M)E-mail: [email protected]

Dr. P.K. Asokan EC Member-CSIAnagha, Pottangadi Raghavan Road West Nadakkavu, Calicut, Kerala 673 011Ph: +91 98470 05074 (M)E-mail: [email protected]

Dr. Rakesh Yadav EC Member-CSI E-25, AV Nagar, August Kranti MargNew Delhi -110 049Ph: +91 98680 26888(M)E-mail: [email protected]

Dr. Narendra Nath Khanna EC Member-CSIL 117, Sarita Vihar, Delhi Mathura Road, New Delhi, 110 076Ph: +91 9810494072E: [email protected]

Dr. Rishi SethiEC Member-CSIB-1/13, Sector-I, Aliganj, Lucknow 226 014Ph: (0522)2255830, +91 9415085717E: drrishisethi1@gmail. com


Names and Addresses of Executive Committee Members of CSI for the year 2017-2018

Dr. Mrinal Kanti Das EC Member-CSI7RC, Rukmani Parasmani92/1, Moulana Abul Kalam Azad Road Kolkata-700054M: +91 98300 34263Email: drmkdas200l@yahoo. co.in

Dr. J. Shivkumar Rao EC Member-CSIPlot No. 30, Vahini Nagar, Sikh Road Secunderabad, TelanganaPin: 500 009Ph: (040)27846080, +91 99899 14440E: [email protected]

Dr. S. Ramakrishnan EC Member-CSIC-14D, DDA Flats, Munrika, New Delhi -110 067Ph: +91 98181 86179(M)E-mail: [email protected]

Dr. B.P. Singh EC Member-CSIE-3/, IGIMS Campus, Sheikhpura, Patna, Bihar-800 014Ph: +91 94310 17889(M)E-mail: [email protected]

Dr. S. Shanmugasundaram EC Member - CSI Senate 3B, 15/61, Gajapathy Street, Shenoy Nagar, Chennai -600030Ph: +91 98400 77173 (M)E-mail: [email protected] Dr. Niteen V. Deshpande EC Member-CSI201, Samruddhi Classic1-A, Khare Town, Dharampeth Nagpur, Maharashtra 440 012Ph: (0712)2443333, +91 98230 56722Email: [email protected]

Dr. Trinath Kumar MishraEC Member-CSIDept. of Cardiology, ICVS, SCBMCH Cuttack, Odisha 753 007Ph: +91 94370 35038E: [email protected]

Dr. Nitish NaikJoint Secretary-CSID-II/85, West Kidwai Nagar New Delhi 110023M: +91 98104 16170Email: [email protected]

Dr. Debabrata Roy Assistant SecretaryCD-19, Sector-1, Salt Lake CityKolkata -700064Tel: (033)23216492, +91 98303 41087(M)E-mail: [email protected] Dr. Ajay J. SwamyCSI-EC Member Co-opted(From Armed Forces)Cardiologist, Army Hospital (R&R)Delhi Cant., New Delhi 110 010 Ph: +91 9650097303E: [email protected]

Dr. J. C. GhosePast President-CSI FE 9, Salt Lake City, Kolkata -700 091Ph: (033)23373431

Dr. M. Khalilullah Past President-CSI2, Ring Road; Lajpatnagar-4New Delhi 110 024Ph: +91 98100 33807, +91 98180 05036E: [email protected]


Conveners of CSI Sub-Speciality Council for 2018 & 2019

Dr. A. Sreenivas Kumar Chairman, National Interventional CouncilChief Cardiologist, Citizens Hospitals, Nallagandla,Serillingampally Mandal, Hyderabad, Telangana 500 019Ph: +91 98480 46785 | E: [email protected] Dr. Dhiman KahaliConvenerCSI- STEMI Sub-speciality Council294 Jodhpur Park, Kolkata 700 068Ph: (033)24734291, +91 98300 48563E: [email protected] Dr. (Wg. Cdr.) S.S. Iyengar ConvenerCSI-LIPID Sub-speciality Council133, J.V. Towers, NGEF Layout, Sadanand Nagar, Benniganhalli, Karnataka 560 038Ph: +91 9845116933 | E: [email protected] Dr. Ambuj RoyConvenerCSI-Heart Failure Council, N4/3, Mulstory Apartment, Sector 13, R.K.Puram, New Delhi 110 066Ph: +91 98109 92822 | E: [email protected] Dr. K. Sivakumar ConvenerCongenital Heart Disease, CSI-Sub Speciality CouncilFlat 1 B, West Moor, Fairmont Garden, Manapakkam, Chennai 600 089Ph: (044)22492643, +91 94444 49966E: [email protected] Dr. Mona BhatiaConvener – Cardiac Imaging, CSI Sub-Speciality CouncilC-13, Soami Nagar, New Delhi 110 017Ph: +91 88006 11612E: [email protected] Dr. Praveen Kr. JainConvener – Hypertension,CSI Sub-Speciality CouncilLifeline Superspeciality Hospital & Heart CentreNear Bundelkhand University, Kanpur Road, Jhansi, Uttar Pradesh 284 128Ph: (0510)2320983/183, +91 94150 30615E: [email protected]

Dr. Neil Bardoloi Convener – Preventive CardiologyCSI Sub-Speciality Council, Goipinath Bhawan, Dr. B K Kakoti Road, Ulubari, Guwahati, Assam, 781 007Ph: (0361)2523942, +91 9435703742E: [email protected] Dr. Aditya KapoorConvener – Cardiac Rhythm CouncilCSI Sub Speciality CouncilType V/16, New Campus, SGPGIMS, Raebareli Road, Lucknow, Uttar Pradesh 226 014Ph: +91 98390 08893 | E: [email protected] Dr. Shantanu Pradeep Sengupta Convener – Echo CardiographyCSI Sub Speciality CouncilSengupta Hospital & Research InstituteRavindra Square, Nagpur, Maharashtra 440 033Ph: (0712)2532697, +91 99231 90925, +91 98235 70925E: [email protected] Dr. S.N. RoutrayConvener – Registry DataCSI Sub Speciality councilQtr. No. 3R-8, Doctor’s Flat, Near Cancer Wing,SCB Medical College, Cuttack, Odisha 753 007Ph: (0671)2305272, +91 94372 25072E: [email protected] Dr. S. Abdul Khadar ConvenerRheumatic Heart Disease, CSI-Sub Speciality CouncilSitara, Near Police Quarters, Gandhinagar, Kottayam, Kerala 686 008Ph: (0481)2598827, +91 98463 25988E: [email protected]


Abbreviation Conference Month Dates Venue

ACC American College of Cardiology Mar 10-12 Orlando, FloridaLINC AP LINC Asia Pacific Mar 13-15 Hong KongEHRA European Heart Rhythm Association Mar 18-20 Barcelona, SpainCIT China Interventional Therapeutics Mar 22-25 Suzhou, ChinaAfrica PCR Africa PCR Mar 25-27 Cape Town, SAEuro GUCH Adult Congenital Heart Disease Apr 20 Munster, GermanyTCT-AP TCT-Asia Pacific Apr-May 28-1 Seoul, KoreaHRS Heart Rhythm Society May 9-12 Boston USACSI-NIC CSI National Interventional Council May 11-13 Hyderabad, IndiaEZECHO 2018 Eastern Zonal Echocardiogrphy Conference May 18-20 Kolkata, IndiaEUROPCR Paris Course on revascularization May 22-25 Paris, FranceESC-HF ESC-Heart Failure May 26-29 Vienna, AustriaIJCTO Indo Japanese CTO Club Jun 1-3 Hyderabad, IndiaBCS BCS-Annual Conference Jun 4-6 Manchester, UKCTO Club Angioplasty of CTO Jun 15-16 Nagoya, JapanEIICCON 2018 Eastern India Interventional Cardiology Conclave Jun 16-17 Kolkata, IndiaC3 Complex Cardiovascular Catheter Therapeutics Jun 17-20 Orlando, FloridaTVT 2018 Trans-vascular Therapeutics Jun 20-22 Chicago, USASVS Society of Vascular Surgery Jun 20-23 Boston, USAICI-CSI CSI-Imaging and Innovation Jun 27-30 Frankfurt, GermanyTOPIC Tokyo Percutaneous Intervention Conference Jul 12-14 Tokyo, JapanWorld Congress of Heart Disease World Congress of Heart Disease Jul 27 Boston, USA

ANZET Annual Australia and New Zealand Endovascular therapies meeting Aug 3-5 Brisbane, Australia

ESC ESC Congress Aug 25-29 Munich, GermanyPCR-London-Valves PCR-London Valves Sep 9-11 London, UKHFSA Heart Failure Society of America Sep 15 Nashville, USATCT Transcatheter Cardiovascular Therapeutics Sep 21-25 San Diego, California

ECHO INDIA 2018 Annual Conference of Indian Academy of Echocardiography Oct 4-7 Chennai, India

CCT Complex Cardiovascular Therapeutics Oct 25-27 Kobe, JapanCSICON 2018 Cardiological Society of India Annual Conference Nov 22-25 Mumbai, IndiaEuroEcho EuroEcho Imaging 2018 Dec 5 Milan, Italy

Upcoming Cardiology Conferences for the year 2018


Guidelines for the BranchesCardiological Society of India1. All CSI branches (city and State branches) shall be

under the administrative control of the parent body.

2. Branches must follow the Constitution of the CSI with regard to membership, elections, functions of the office-bearers and aims & objectives.

3. Each branch should have its own articles of association and rules and regulations registered with the registrar of societies. This is needed as the composition of the executive committee and the scientific committee will depend upon the existing strength of the members and is likely to be at variance with that of the parent body.

4. Branches should use correct logo and stationery in conformation with that approved for the parent body.

5. New branches to be created should follow the state-wise pattern (pre-existing branches would not be disturbed). City branches should have affiliation to the state branch and the state branches should be directly responsible to the parent body. Zonal branches, if formed, must have membership from contiguous states and union territories and not from one state/city only. It is desired that correct nomenclature of the branches be followed to avoid confusion and overlap.

6. Branches should have regular elections at least once in every two years. It would be the joint as well as separate responsibility of the Secretary and the President of the outgoing executive committee to send the notification regarding newly elected office bearers to the parent body. If there is no election for two or more consecutive terms, the branch shall stand dissolved and all money/assets owned by it shall vest with the parent body till alternative arrangements are made. Bankers of the branches must be given a copy of this resolution at the time of opening of the branch or when the office bearers change.

7. The election of the branch body should be direct with all members offered an opportunity to participate. Number of office bearers would not exceed 10% of the current membership with a minimum of four office bearers. There should be no provision for nomination although the articles of association should mention the method of filling of any interim

vacant post. All such decisions should be ratified by the general body with a copy to the parent body.

8. Each branch should have its own bank account, PAN, TDS number and 80G certificate. This should be communicated to the parent body as soon as it becomes available. However, the parent body shall not share any financial liability. All tax matters will be the responsibility of the branch. No proceedings would be permissible against office bearers of the parent body (CSI) for the lapses of the branches.

9. Audited accounts of the branch should be submitted every year to the HQs.These will be shown as annexures in the annual report of the CSI parent body. Only the portion of the money which are physically transferred to the accounts of the HQs shall form part of the latter’s accounts. Failure to submit audited accounts for two or more consecutive terms without a valid and acceptable reason shall result in dissolution of the branch. The names of auditors and bankers must be communicated to the HQs. The HQs shall reserve the right for external audit in case of complaints, if any.

10. A branch must periodically (once in six months) submit a report of its activities to the Headquarters.

11. Branches shall enjoy complete financial autonomy with regards to the funds collected by them. However, wherever a large capital expenditure of more than Rs.5 lakhs is contemplated, prior permission of the HQs should be obtained. Each branch should make a provisional budget in advance and seek approval from its own general body.

12. Branches are expected to optimally utilise the resources and it is desirable to send a periodic report about it to the HQs.

13. All disputes and disagreements related to any branch shall have final arbitration by the national executive committee of the CSL

14. A member either ordinary or Life Member of the Central CSI could be ordinary or Life Member of the Branch. Others could only be Associate member of the branch.

15. To open a branch, the required number of members should be 25.


Proforma for Updating Members’ Directory of Cardiological Society of India

Name .........................................................................................................................

(BLOCK LETTERS) (First Name) (Middle Name) (Surname)

C.S.I. Membership No.: .........................................................................................................................

Address for Correspondence: .........................................................................................................................

(BLOCK LETTERS)

.........................................................................................................................

.........................................................................................................................

Phone: Residence: .........................................................................................................................

Mobile: .........................................................................................................................

Fax: .........................................................................................................................

E-mail: .........................................................................................................................

Specimen Signature: .........................................................................................................................


Glimpses of 69th Annual Conference of CSI, Kolkata 2017











CSI AS A CONSCIENTIOUS NATIONAL BODY — Dr M K Das, Immediate Past Hony. General Secretary and current EC member represented CSI at DOCTORS’ MAHAPANCHAYAT organised by IMA on 25th March ’18 at New Delhi

Date post:	28-May-2020
Category:	Documents
Upload:	others
View:	1 times
Download:	0 times

Robert Frost. › pdf › News_Letter_2018.pdf · Best wishes to all of you. Dr. K. Sarat Chandra...

Documents